Bluejay Diagnostics, Inc.
NCM: BJDXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Bluejay Diagnostics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get BJDX Z-Score →About Bluejay Diagnostics, Inc.
Healthcare
Medical Devices
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
📊 Fundamental Analysis
Bluejay Diagnostics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -117.0%, which indicates that capital utilization is currently under pressure.
At a current price of $1.78, BJDX currently trades near the bottom of its 52-week range (1%), indicating potential value or weakness (Range: $1.65 - $16.68).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$1.84M
Trailing P/E
--
Forward P/E
-5.56
Beta (5Y)
0.67
52W High
$16.68
52W Low
$1.65
Avg Volume
231K
Day High
Day Low